GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » E10

CytoDyn (CytoDyn) E10 : $-0.31 (As of Feb. 2024)


View and export this data going back to 2005. Start your Free Trial

What is CytoDyn E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

CytoDyn's adjusted earnings per share data for the three months ended in Feb. 2024 was $-0.010. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.31 for the trailing ten years ended in Feb. 2024.

During the past 3 years, the average E10 Growth Rate was -3.20% per year. During the past 5 years, the average E10 Growth Rate was -1.70% per year. During the past 10 years, the average E10 Growth Rate was -3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of CytoDyn was -1.10% per year. The lowest was -8.00% per year. And the median was -3.35% per year.

As of today (2024-06-06), CytoDyn's current stock price is $0.1513. CytoDyn's E10 for the quarter that ended in Feb. 2024 was $-0.31. CytoDyn's Shiller PE Ratio of today is .


CytoDyn E10 Historical Data

The historical data trend for CytoDyn's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn E10 Chart

CytoDyn Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.33 -0.30 -0.33 -0.35 -0.33

CytoDyn Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -0.33 -0.32 -0.31 -0.31

Competitive Comparison of CytoDyn's E10

For the Biotechnology subindustry, CytoDyn's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoDyn's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where CytoDyn's Shiller PE Ratio falls into.



CytoDyn E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CytoDyn's adjusted earnings per share data for the three months ended in Feb. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=-0.01/130.9299*130.9299
=-0.010

Current CPI (Feb. 2024) = 130.9299.

CytoDyn Quarterly Data

per share eps CPI Adj_EPS
201405 -0.050 100.373 -0.065
201408 -0.060 100.352 -0.078
201411 -0.090 99.635 -0.118
201502 -0.050 99.032 -0.066
201505 -0.240 100.333 -0.313
201508 -0.120 100.548 -0.156
201511 -0.060 100.135 -0.078
201602 -0.050 100.040 -0.065
201605 -0.050 101.355 -0.065
201608 -0.040 101.617 -0.052
201611 -0.040 101.829 -0.051
201702 -0.060 102.779 -0.076
201705 -0.050 103.256 -0.063
201708 -0.080 103.587 -0.101
201711 -0.070 104.072 -0.088
201802 -0.100 105.052 -0.125
201805 -0.040 106.148 -0.049
201808 -0.070 106.383 -0.086
201811 -0.060 106.338 -0.074
201902 -0.040 106.649 -0.049
201905 -0.050 108.048 -0.061
201908 -0.040 108.245 -0.048
201911 -0.040 108.519 -0.048
202002 -0.080 109.139 -0.096
202005 -0.160 108.175 -0.194
202008 -0.060 109.662 -0.072
202011 -0.060 109.793 -0.072
202102 -0.080 110.968 -0.094
202105 -0.110 113.576 -0.127
202108 -0.070 115.421 -0.079
202111 -0.060 117.269 -0.067
202202 -0.060 119.703 -0.066
202205 -0.120 123.323 -0.127
202208 -0.030 124.958 -0.031
202211 -0.030 125.607 -0.031
202302 -0.020 126.928 -0.021
202305 -0.020 128.314 -0.020
202308 -0.010 129.538 -0.010
202311 -0.010 129.548 -0.010
202402 -0.010 130.930 -0.010

Add all the adjusted EPS together and divide 10 will get our e10.


CytoDyn  (OTCPK:CYDY) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


CytoDyn E10 Related Terms

Thank you for viewing the detailed overview of CytoDyn's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoDyn (CytoDyn) Business Description

Traded in Other Exchanges
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Executives
Tyler Blok officer: EVP of Legal Affairs 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Stephen M Simes director
Ryan Dunlap director 310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034
Arvin Cyrus Arman officer: President 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Karen J Brunke director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Tanya Durkee Urbach director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Lishomwa C Ndhlovu director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Harish Seethamraju director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Gordon A Gardiner director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Samir Rashmikant Patel director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Antonio Migliarese officer: Chief Financial Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Chris P Recknor officer: Chief Operating Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Michael D. Mulholland officer: CFO, Treasurer and Secretary 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Jordan G Naydenov director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660

CytoDyn (CytoDyn) Headlines

From GuruFocus

CytoDyn to Hold Webcast to Provide a Quarterly Company Update

By PurpleRose PurpleRose 07-12-2022

CytoDyn to Hold Webcast to Provide a Quarterly Company Update

By GuruFocusNews GuruFocusNews 06-22-2022

CytoDyn Announces President Takes Medical Leave of Absence

By sperokesalga sperokesalga 05-24-2023